Page Image

Triple-Negative Breast Cancer

Back to Homepage
Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest Updates in Breast Cancer

April 24, 2025